{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immunotherapy+plus+chemotherapy", "query": { "intervention": "Immunotherapy plus chemotherapy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 599, "total_pages": 60, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immunotherapy+plus+chemotherapy&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-22T03:44:41.020Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02892123", "title": "Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-expressing Cancers" ], "interventions": [ { "name": "ZW25 (Zanidatamab)", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Tucatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 279, "start_date": "2016-09-30", "completion_date": "2024-10-31", "has_results": false, "last_update_posted_date": "2024-11-27", "last_synced_at": "2026-09-22T03:44:41.020Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02892123" }, { "nct_id": "NCT02004262", "title": "Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "GVAX Pancreas Vaccine", "type": "BIOLOGICAL" }, { "name": "CRS-207", "type": "BIOLOGICAL" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Aduro Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 303, "start_date": "2014-02-05", "completion_date": "2016-08-23", "has_results": true, "last_update_posted_date": "2018-06-04", "last_synced_at": "2026-09-22T03:44:41.020Z", "location_count": 20, "location_summary": "Scottsdale, Arizona • La Jolla, California • San Francisco, California + 16 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02004262" }, { "nct_id": "NCT01903083", "title": "Chemoimmunotherapy and Radiation in Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Malignant Neoplasm" ], "interventions": [ { "name": "Tadalafil", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Pancreaticoduodenectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2013-07", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2018-02-01", "last_synced_at": "2026-09-22T03:44:41.020Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01903083" }, { "nct_id": "NCT01530269", "title": "C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer", "Prostate Adenocarcinoma" ], "interventions": [ { "name": "C11-Sodium Acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Phoenix Molecular Imaging", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "MALE", "summary": "18 Years to 90 Years · Male only" }, "enrollment_count": 300, "start_date": "2012-04", "completion_date": "2019-01", "has_results": false, "last_update_posted_date": "2019-03-07", "last_synced_at": "2026-09-22T03:44:41.020Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01530269" }, { "nct_id": "NCT04836429", "title": "Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Non-Small Cell Carcinoma", "Pleural Disorder" ], "interventions": [ { "name": "Porfimer Sodium", "type": "DRUG" }, { "name": "Video-Assisted Thoracic Surgery", "type": "PROCEDURE" }, { "name": "Photodynamic Therapy", "type": "DRUG" }, { "name": "Intraoperative PDT", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "DEVICE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2022-03-10", "completion_date": "2025-01-03", "has_results": false, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-09-22T03:44:41.020Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04836429" }, { "nct_id": "NCT03450122", "title": "Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HLA-A*0201 Positive Cells Present", "NY-ESO-1 Positive Tumor Cells Present", "Recurrent Myxoid Liposarcoma", "Recurrent Synovial Sarcoma" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Autologous NY-ESO-1-specific CD8-positive T Lymphocytes", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Dendritic Cell-targeting Lentiviral Vector ID-LV305", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2018-09-13", "completion_date": "2022-12-06", "has_results": false, "last_update_posted_date": "2023-10-16", "last_synced_at": "2026-09-22T03:44:41.020Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03450122" }, { "nct_id": "NCT04554914", "title": "A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Epstein-Barr Virus (EBV)-Associated Diseases", "EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)", "EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD)", "EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)", "EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD)", "Solid Organ Transplant Complications", "Lymphoproliferative Disorders", "Allogeneic Hematopoietic Cell Transplant", "Stem Cell Transplant Complications", "EBV+ Sarcomas", "Leiomyosarcoma" ], "interventions": [ { "name": "Tabelecleucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pierre Fabre Medicament", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 190, "start_date": "2021-07-14", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-09-22T03:44:41.020Z", "location_count": 23, "location_summary": "Los Angeles, California • Orange, California • Palo Alto, California + 18 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04554914" }, { "nct_id": "NCT07680764", "title": "A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Non-Small Cell Lung Cancer (NSCLC)", "Metastatic Non-Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Pumitamig", "type": "DRUG" }, { "name": "Imzokitug", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Vedolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2026-08-31", "completion_date": "2030-09-15", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-09-22T03:44:41.020Z", "location_count": 10, "location_summary": "Athens, Georgia • Lexington, Kentucky • Baltimore, Maryland + 6 more", "locations": [ { "city": "Athens", "state": "Georgia" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Hattiesburg", "state": "Mississippi" } ], "official_url": "https://clinicaltrials.gov/study/NCT07680764" }, { "nct_id": "NCT03635632", "title": "C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Neuroblastoma", "Refractory Neuroblastoma", "Relapsed Osteosarcoma", "Relapsed Ewing Sarcoma", "Relapsed Rhabdomyosarcoma", "Uveal Melanoma", "Phyllodes Breast Tumor" ], "interventions": [ { "name": "C7R-GD2.CART cells", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "74 Years", "sex": "ALL", "summary": "1 Year to 74 Years" }, "enrollment_count": 94, "start_date": "2019-04-23", "completion_date": "2038-05-16", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-09-22T03:44:41.020Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03635632" }, { "nct_id": "NCT04049669", "title": "Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Medulloblastoma", "Ependymoma", "Diffuse Intrinsic Pontine Glioma" ], "interventions": [ { "name": "Indoximod", "type": "DRUG" }, { "name": "Partial Radiation", "type": "RADIATION" }, { "name": "Full-dose Radiation", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Theodore S. Johnson", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 130, "start_date": "2019-10-02", "completion_date": "2027-10-02", "has_results": false, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-09-22T03:44:41.020Z", "location_count": 5, "location_summary": "Augusta, Georgia • Druid Hills, Georgia • Boston, Massachusetts + 2 more", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Druid Hills", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04049669" } ] }